Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 139 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuromuscular Inhibition Clear all
Completed Phase 3 Interventional Results available

Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant

NCT03116997
View directory record Official record
Conditions
Surgery
Interventions
Neostigmine+glycopyrrolate, Sugammadex
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

NCT05687253
View directory record Official record
Conditions
Neuromuscular Blockade, Anesthesia, Surgery
Interventions
BX1000, Rocuronium Bromide
Drug
Lead sponsor
Baudax Bio
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Phase 4 Interventional Results available

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

NCT03346057
View directory record Official record
Conditions
Reversal of Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 7, 2026, 12:23 AM EDT
Completed No phase listed Observational

Suggamadex and Fast-track Cardiac Anesthesia in a Developing Country

NCT02704351
View directory record Official record
Conditions
Suggamadex, Surgery for Congenital Heart Disease
Interventions
Surgery
Procedure
Lead sponsor
Joseph D. Tobias
Other
Eligibility
0 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 7, 2026, 12:23 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Not applicable Interventional Results available

Electromyographic and Acceleromyographic Monitoring in Restricted Arm Movement Surgical Setting

NCT04352140
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Tetragraph, ToFscan
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Phase 3 Interventional

Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery

NCT03513406
View directory record Official record
Conditions
Burns
Interventions
Sugammadex, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 7, 2026, 12:23 AM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

NCT01724580
View directory record Official record
Conditions
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI), Aicardi-Goutières Syndrome (AGS)
Interventions
Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 7, 2026, 12:23 AM EDT
Terminated Phase 1 Interventional

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

NCT04330625
View directory record Official record
Conditions
Hyperglycemia Drug Induced
Interventions
REMD-477
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 7, 2026, 12:23 AM EDT
Not listed No phase listed Observational

Effect of Randomization to Neuromuscular Blockade on Physical Functional Impairment and Recovery in ARDS

NCT03038906
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Neuromyopathies
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Not applicable Interventional

Muscle Relaxation Therapy With Odorant Cue

NCT00208910
View directory record Official record
Conditions
Generalized Anxiety Disorder, Anxiety
Interventions
Odorant Cue
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 7, 2026, 12:23 AM EDT
Recruiting Phase 2 Interventional

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

NCT06463028
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sapanisertib, Serabelisib, Paclitaxel
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
La Jolla, California • San Francisco, California • Miami Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 7, 2026, 12:23 AM EDT
Withdrawn Phase 2 Interventional

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

NCT03376854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Sars-CoV2
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of Care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers

NCT00999128
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GDC-0941, rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Phase 4 Interventional Results available

Propofol for Pediatric Tracheal Intubation With Deep Anesthesia During Sevoflurane Induction

NCT01150838
View directory record Official record
Conditions
Anesthesia Intubation Complication
Interventions
propofol
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year to 11 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Sep 7, 2026, 12:23 AM EDT
Recruiting No phase listed Observational

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

NCT04202341
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
32
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 7, 2026, 12:23 AM EDT
Completed No phase listed Observational

Comparing Train-of-Four Recovery in the Adductor Pollicis Versus the Adductor Digiti Minimi in Elective Surgery Patients

NCT06467448
View directory record Official record
Conditions
Anesthesia, Neuromuscular Blockade
Interventions
EMG Assessement of Recovery of Neuromuscular Function
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Not applicable Interventional Results available

Thumb vs Great Toe Recovery

NCT04312256
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
TetraGraph
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurophysiology of Weakness and Exercise in Rotator Cuff Tendinopathy

NCT02971072
View directory record Official record
Conditions
Acute Pain, Atrophic, Goals, Impairment, Infiltration, Injury, Muscle Weakness, Pain, Pathology, Shoulder Pain, Syndrome, Tendinopathy
Interventions
Subacromial injection, Physical Therapy
Procedure · Other
Lead sponsor
University of Oregon
Other
Eligibility
21 Years to 45 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Phase 4 Interventional Results available

Quality of Recovery After Reversal With Neostigmine or Sugammadex.

NCT02909439
View directory record Official record
Conditions
Incomplete Reversal of Neuromuscular Block
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Sep 7, 2026, 12:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Electromyographic Assessment of the TetraGraph in Normal Volunteers

NCT02912039
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
TetraGraph, TOF Watch
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 7, 2026, 12:23 AM EDT
Completed Not applicable Interventional Results available

Resiliency Among Older Adults Receiving Lung Cancer Treatment

NCT04229381
View directory record Official record
Conditions
Advanced Lung Carcinoma, Extensive Stage Lung Small Cell Carcinoma, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Carcinoma, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Physical Therapy, Quality-of-Life Assessment, Questionnaire Administration, Relaxation Therapy
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 7, 2026, 12:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

NCT06735820
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1), Atypical Neurofibroma
Interventions
APG-115, Selumetinib
Drug
Lead sponsor
AeRang Kim
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 7, 2026, 12:23 AM EDT